Healthcare, Pharma & Life Sciences

PRINCETON, N.J. – November 10, 2026 -- CytoSorbents Corporation (NASDAQ: CTSO) will send CEO Dr. Phillip Chan and CFO Peter Mariani to the Jefferies Global Healthcare Conference in London on November 16-18, 2026, for one-on-one investor meetings.

Investors can book CytoSorbents management meetings through the Jefferies conference website

Meetings can be scheduled through the conference website, or through the company's investor relations team for sessions outside the event. The conference is in its 17th year and is Jefferies' flagship European healthcare investment gathering. It draws C-suite executives, public, private equity and venture capital investors, and strategists across biotech, pharmaceuticals, medical technology, healthcare services, digital health and healthcare IT.

New York – November 09, 2026 -- An AI tool called PREVIA flagged 100 percent of 30 emergency department patients who went on to develop post-traumatic stress disorder (PTSD), while a PTSD-specialist ED clinician identified 89 percent of the same cases, according to a study led by NYU Langone Health.

PREVIA identifies more than 95.4 percent of at-risk patients from 145 trauma narratives

The study, published November 9 in Nature Communications, ran a set of AI models on the recorded and transcribed trauma narratives of 145 ED patients. The models correctly identified more than 95.4 percent of at-risk patients. Results were validated against diagnoses from the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), the gold-standard clinical interview.

MIAMI – November 09, 2026 -- OpenEvidence will license clinical guidance from the American College of Physicians (ACP) and peer-reviewed content from Annals of Internal Medicine, adding the content to its AI clinical decision support platform for U.S. physicians.

ACP is the largest medical specialty organization in the United States. OpenEvidence describes itself as the most popular AI for doctors in the country.

ACP guidelines and journal content move into the point-of-care workflow

The licensed material covers ACP's clinical guidelines, guidance statements, practice points and best practice advice. It also covers Annals of Internal Medicine content, which includes original research, review articles, clinical guidelines and commentary on clinical practice, health care delivery, public health, policy, medical education, ethics and research methodology.

Castres – November 09, 2026 -- Laboratoires Pierre Fabre and XtalPi Holdings Limited (2228.HK) have signed a drug discovery agreement that includes an upfront payment, multiple milestone payments and downstream economic participation. Neither company disclosed the financial terms.

XtalPi to design small molecules de novo against undisclosed targets

XtalPi will apply its integrated AI capabilities and robotics platform to design and deliver novel small molecule therapeutics. The research programs cover oncology, potentially dermatology, and rare diseases. The targets were not named.

Pierre Fabre takes on compound selection and clinical and commercial development

Pierre Fabre will contribute expertise in disease biology, discovery, translational research and clinical development to select and advance the most promising compounds. It will also be responsible for subsequent clinical and commercial development.

OSLO, Norway – November 09, 2026 -- Photocure ASA (OSE: PHO) said the Medicare coverage timeline for its AssureMDx bladder cancer test remains in line with its original acquisition assumptions, after the test was left out of a newly published Novitas Local Coverage Determination (LCD) dated November 6, 2026. Pricing talks, however, point to a potential reimbursement level "meaningfully above" the assumptions in the company's initial underwriting.

Photocure planned for 2028 Medicare coverage when it bought Vesica Health

When Photocure acquired Vesica Health on June 4, 2026, its planning assumption was Medicare coverage in 2028, following submission of additional clinical evidence. A proposed Novitas LCD in May 2026 had raised the prospect of an earlier decision. The final LCD covers urine-based biomarkers in patients with microhematuria but does not include AssureMDx. It identifies additional clinical evidence needed for future reconsideration.

Nanjing – November 09, 2026 -- PharmaBlock hosted a two-day CMC Lifecycle Strategy Forum in Nanjing on November 5 and 6, gathering experts with senior R&D experience at AstraZeneca, AbbVie, Bayer and Pfizer to debate how stage-appropriate chemistry, manufacturing and controls (CMC) decisions can improve development efficiency.

Professionals from Seda Pharmaceutical, Jacobio Pharma, Benemae and PharmaBlock also took part. The agenda covered candidate developability, solid-state science, model-informed drug development, clinical supply and commercial manufacturing.

Warsaw – November 09, 2026 -- Ingenix's "Thalamus Reasoning" model ranks first among 29 models on LongevityBench, the independent benchmark for language models in cellular aging research, with a mean rank of 1.42 across the benchmark's 14 ranked tasks. The next best model scores 4.42. The best frontier model, Claude Opus 4.6, scores 9.85.

Ingenix's 9-billion-parameter model wins 11 of 14 benchmark tasks

The model was built by a small team and outperforms 28 published models, including systems from leading frontier labs. It also beats the best non-LLM baseline on eight tasks.

On DNA methylation age prediction, Thalamus Reasoning posts an error of 3.36 years. The best text-prompted model on the same Qwen3.5-9B base scores 12.9 years, and the Horvath clock scores 4.67 years. On transcriptomics ordering, the model reaches 0.828 accuracy against 0.671 for the best other LLM.

New York and Stockholm – November 09, 2026 -- The Galien Foundation has named 45 nominees and products for the 2026 Prix Galien Bridges Awards and chosen HealthCap founder Björn Odlander as recipient of the Bengt I. Samuelsson "True North" Award. The ceremony takes place December 1, 2026, at the Medicinska Föreningen at Karolinska Institutet in Stockholm.

Awards span seven categories from drugs to public sector innovation

Nominees compete in seven categories: Best Pharmaceutical Agent, Best Biotechnology Product, Best Product for Rare/Orphan Diseases, Best Medical Technology / AI Advances in Human Health, Best Enabling Technology for Medical Innovation, Best Public Sector Innovation and Best Bridge-Builder Institution.

Munich – November 09, 2026 -- No video carries a verified subtitle track at 36 of 50 medical technology companies examined, or 72%, according to an audit by purple.audio, the transcription platform of Spotwatch GmbH.

Only 34 of 578 product and training videos carry checked subtitles

Across 578 videos on products, applications and training, 34 (5.9%) have a verified subtitle track. Another 155 run on unverified machine-generated text, and 389 have no subtitle track at all.

None of the 885 videos reviewed has a detectable audio description track.

Company-run players omit subtitles in 325 of 346 spoken-word videos

In companies' own video players, the subtitle track is missing from 325 of 346 videos containing speech. In 283 of 497 cases, the page code lacked even the control for switching subtitles on.

NEW TAIPEI CITY – November 08, 2026 -- GlycoNex (TPEx: 4168) has submitted a marketing authorization application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for SPD8, its denosumab biosimilar candidate, with approval possible as early as the end of 2027.

The timeline is subject to PMDA review. SPD8 was co-developed with Mitsubishi Gas Chemical (MGC). Preparations for a separate submission in Taiwan are also underway.

Phase 3 trial in 266 osteoporosis patients met its primary endpoint

The filing follows positive topline results from a randomized, double-blind, multicenter Phase 3 trial in Japan. The study enrolled 266 patients with osteoporosis. It demonstrated therapeutic equivalence to reference denosumab, measured by the percentage change from baseline in lumbar spine bone mineral density at Month 12.